Study 34 of 34Orforglipron (LY-3502970) literatureLancet (London, England)Top journal2026
Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.
Not reported in abstract.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpus10
Preclinical · this one
8
Observational
1
Open-label
8
Randomised
7
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Orforglipron (LY-3502970) corpus
AQualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.The patient · 2023 · n=60 · Patients reduced glycated hemoglobin by 1.6% (SD = 1.3) from a baseline of 8.3%.HumanACardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.Lancet (London, England) · 2026 · HR 0.84; 95% CI 0.59-1.20; p<0.0001 for non-inferiority.HumanDEstablishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.Lancet (London, England) · 2026—BOral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Usersbiorxiv-preprint · 2026 · Mean weight change by 90 days was -3.1% with oral Wegovy (n=26) versus +0.4% with Foundayo (n=18), corresponding to a 3.55-percentage-point difference (95% CI, 1.02-6.08; P=0.007).HumanDEfficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programsbiorxiv-preprint · 2026 · Pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%)reviewAOrforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.The Annals of pharmacotherapy · 2026 · mean 7.1% to 10.6% placebo-adjusted weight reduction with orforglipronreview